茚达特罗在慢性阻塞性肺疾病治疗中效果分析

摘要

Objective To investigate the clinical efficacy and safety of Indatero in the treatment of COPD.Methods Through adopting randomized controlled trial,80 patients were randomly divided into A and B groups,with 40 patients in each group.Patients in A Group were delivered Indaterol treatment while Group B patients were delivered formoterol treatment.In the follow-up after 1 d, 30 d and 90 d, the clinical efficacy was evaluated and the safety was monitored before and after the treatment.Results 1 d,30 d and 90 d after the treatment, the FEV1 of patients in Group A were higher than those in Group B,and the FEV1 improvement in Group A were larger than those in Group B(P<0.05);BODE index in Group A was lower than those in group B, and the BODE index decrease in Group A was larger than those in Group B(P<0.05);SGRO score in Group A was lower than those in Group B, and the Group A score decrease was larger than that in Group B(P<0.05);the adverse events in A and B Groups didn′t have obvious difference(P>0.05).Conclusion Indene Datlow has fast reaction,continuous and stable clinical efficacy, and high security.It can obviously improve the pulmonary ventilation function,condition and living quality,which makes it worthy of clinical application and popularization.%目的：探讨茚达特罗在慢性阻塞性肺疾病（ COPD）治疗中的临床疗效及安全性。方法采用随机对照实验进行研究，将80例患者随机分为A、B组，每组各40例。 A组患者使用茚达特罗治疗，B组患者使用福莫特罗治疗。在治疗前和治疗后进行疗效评价，对治疗1 d后、30 d后及90 d后进行随访，评价疗效，监测其安全性。结果在治疗1 d后、30 d后及90 d后，A组患者FEV1均高于B组患者FEV1，A组患者FEV1差值均比B组患者FEV1差值大（P＜0．05）；A组患者BODE指数均低于B组患者BODE指数，A组患者BODE指数减少均比B组多（P＜0．05）；A组患者SGRO分数均低于B组患者SGRO分数，A组患者SGRO分数减少均比B组多（P＜0．05）。在随访的90 d里，A、B两组治疗不良事件发生情况并未有明显的差异（P＞0．05），发生率较低。结论茚达特罗具有起效快，作用持续，效果稳定，治疗简便等特点，能明显改善COPD患者的肺通气功能，疗效项目，能改善患者病情和预后，安全性高，值得临床推广应用。